

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### The effects of a newly designed natural sweetener (Lacritose) compared to sucrose and glucose on blood glucose concentrations and possible gastrointestinal reactions in patients with type 2 diabetes: a double-blind randomized three way cross-over clinical trial

#### Protocol summary

##### Summary

**Aims and design:** The present study will explore the effect of the sweetener Lacritose compared with sucrose and glucose in patients with type 2 diabetes. This study will be a double-blind three way cross-over clinical trial on type 2 diabetic patients. All the participants (n=20) will undergo three treatment periods (Lacritose, sucrose and glucose) to examine their effect on blood sugar. Sweeteners and their solution in tap water are completely the same. The sweeteners will be marked as A, B and C by a person who is not aware of study objectives and protocols in order to blind both participants and investigators. Then the sweeteners will be dissolved in 300 ml of tap water and the beverages will be ingested by participants. **Methods:** After filling demographic questionnaire height will be measured without shoes by a tape measure fixed on a wall, with 1 centimeter accuracy and weight will be measured by a digital scale with 100 gram accuracy. All participants will randomly ingest the test beverages (Lacritose, sucrose or glucose beverage) when they are in a fasted state on the intervention days. There will be six days as washout period between ingesting each test beverage. Participants will be asked to come to laboratory while they are fasted overnight for 8-12 hours on the intervention days and then they will give blood sample to measure fasting blood sugar levels. 5 ml of blood sample will be taken from each participant to assess the fasting blood sugar levels. Then the test powders (50 grams of Lacritose, sucrose or glucose ) will be given to participants dissolved in 300 ml of tap water. The participants will be asked not to ingest any meals, tea, coffee, smoke or drugs and avoid intense physical activity up to 2 hours after drinking the test drinks. **Outcome measurement:** Subjects will give blood samples every 30 minutes after drinking the test solutions up to 2

hours on blood sugar increase. The gastrointestinal adverse reactions to the sugars will also be checked up to 24 hours after ingesting each test beverage.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT2015050912571N2**

Registration date: **2016-09-15, 1395/06/25**

Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2016-09-15, 1395/06/25

##### Registrant information

##### Name

Amin Salehi-Abargouei

##### Name of organization / entity

Shahid Sadoughi University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 35 3820 9100

##### Email address

abargouei@hlth.mui.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

##### Expected recruitment start date

2016-02-20, 1394/12/01

**Expected recruitment end date**

2016-10-21, 1395/07/30

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

The effects of a newly designed natural sweetener (Lacritose) compared to sucrose and glucose on blood glucose concentrations and possible gastrointestinal reactions in patients with type 2 diabetes: a double-blind randomized three way cross-over clinical trial

**Public title**

The safety and effect of a new sweetener (Lacritose) compared to sugar and glucose on postprandial blood sugar

**Purpose**

Treatment

**Inclusion/Exclusion criteria**

Inclusion criteria: Type 2 diabetic patients (n=20) with fasting blood sugar >125 mg/dl and lower than 200 mg/dl, aged 20 to 60. Exclusion criteria: Participants will not be included in the trial if they were pregnant or lactating, had severe infection, endocrine disorders or acute diseases at the enrollment. Participants who intend to exit with any reasons or show any adverse reaction to test sugars will also be excluded from the study. .

**Age**

From **20 years** old to **60 years** old

**Gender**

Both

**Phase**

2-3

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **20**

**Randomization (investigator's opinion)**

Randomized

**Randomization description****Blinding (investigator's opinion)**

Double blinded

**Blinding description****Placebo**

Used

**Assignment**

Crossover

**Other design features**

Randomization: All Participants will randomly ingest the three intervention beverages [consisting of 50 gram of test sugars (lacritose, sucrose and glucose) and tap water] coded as A, B or C, for one time. The order of ingesting the test beverages (rolling methods) will be randomized by computer using statistical package for social sciences (SPSS) software version 15. Participants will be randomized into 6 rolling methods (ABC, ACB, BCA, BAC, CAB, and CBA). The random order will be written on a paper and will be kept in opaque envelopes

and after presence of subjects in laboratory, the pocket will be opened and the order of ingesting beverages will be revealed for the study team.

**Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Shahid Sadoughi University of Medical Sciences

**Street address**

Faculty of Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

**City**

Yazd

**Postal code****Approval date**

2015-07-01, 1394/04/10

**Ethics committee reference number**

IR.SSU.SPH.REC.1394.31

**Health conditions studied****1****Description of health condition studied**

Non-insulin-dependent diabetes mellitus

**ICD-10 code**

E11

**ICD-10 code description**

non insulin dependent diabetes mellitus

**Primary outcomes****1****Description**

Postprandial blood sugar

**Timepoint**

Every 30 minutes up to 2 hours after ingesting the test beverages

**Method of measurement**

Using pars azmoon kits using automated analyzer

**Secondary outcomes****1****Description**

Gastrointestinal symptoms

**Timepoint**

24 hour after ingesting the test beverages

**Method of measurement**

Gastrointestinal symptoms questionnaire

## Intervention groups

1

### Description

50 grams of Lactitose dissolved in 300 ml of tap water

### Category

Treatment - Drugs

2

### Description

50 grams of sucrose dissolved in 300 ml of tap water

### Category

Placebo

3

### Description

50 grams of glucose dissolved in 300 ml of tap water

### Category

Placebo

## Recruitment centers

1

### Recruitment center

#### Name of recruitment center

Baghaei pour obesity clinic, Shahid sadoughi University of Medical Sciences, Yazd, Iran

#### Full name of responsible person

#### Street address

Baghaei pour obesity clinic, Shahid sadoughi University of Medical Sciences, Yazd, Iran

#### City

Yazd

## Sponsors / Funding sources

1

### Sponsor

#### Name of organization / entity

Vice chancellor for research, Shahid Sadoughi University of Medical Sciences

#### Full name of responsible person

Dr. Amirhushang Mehrparvar

#### Street address

Vice-chancellery for research and technology, Shahid Sadoughi University of Medical Sciences, Bahonar Square, Yazd, Iran.

#### City

Yazd

### Grant name

### Grant code / Reference number

### Is the source of funding the same sponsor organization/entity?

Yes

### Title of funding source

Vice chancellor for research, Shahid Sadoughi University of Medical Sciences

### Proportion provided by this source

100

### Public or private sector

empty

### Domestic or foreign origin

empty

### Category of foreign source of funding

empty

### Country of origin

### Type of organization providing the funding

empty

## Person responsible for general inquiries

### Contact

#### Name of organization / entity

Shahid Sadoughi University of Medical Sciences

#### Full name of responsible person

Dr. Amirhoushang Mehrparvar

#### Position

Vice chancellor for research, Shahid Sadoughi University of Medical Sciences

#### Other areas of specialty/work

#### Street address

Vice-chancellery for research and technology, Shahid Sadoughi University of Medical Sciences, bahonar Square, Yazd, Iran

#### City

Yazd

#### Postal code

#### Phone

+98 35 3726 6711

#### Fax

#### Email

ah.mehrparvar@gmail.com

#### Web page address

## Person responsible for scientific inquiries

### Contact

#### Name of organization / entity

Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, I

#### Full name of responsible person

Dr. Amin Salehi-Abargouei

#### Position

PhD

#### Other areas of specialty/work

#### Street address

Department of Nutrition, Faculty of Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

#### City

Yazd

#### Postal code

#### Phone

+98 35 3820 9100

#### Fax

#### Email

abargouei@gmail.com; abargouei@hlth.mui.ac.ir

#### Web page address

## Person responsible for updating data

### Contact

**Name of organization / entity**

Nutrition and Food Security Research Center, Shahid  
Sadoughi University of Medical Sciences, Yazd, I

**Full name of responsible person**

Mohammad Ali Mohsenpour

**Position**

BSc in Nutrition, MSc Student

**Other areas of specialty/work****Street address**

Department of Nutrition, International Campus,  
Shahid Sadoughi University of Medical Sciences, Yazd,  
Iran.

**City**

Yazd

**Postal code****Phone**

+98 35 3820 9100

**Fax****Email**

mohammadali.mohsenpour@gmail.com

**Web page address**

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*